What insurance policy changes affect code L40.8?

There are 4 tracked policy changes affecting code L40.8, including updates from Independence Blue Cross, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code L40.8?

Payers that have issued tracked updates for code L40.8 include: Independence Blue Cross, Aetna.

How do I get notified when code L40.8 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code L40.8. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code L40.8?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

L40.8 Insurance Policy Changes

ICD-10 L40.8 is officially defined as "Other psoriasis." code L40.8 is referenced in 4 tracked payer policy changes from Independence Blue Cross and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code L40.8 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Independence Blue Cross · Effective Apr 1, 2026Medium impact
MA11.071b, Selective Photothermolysis Using Pulsed-Dye Lasers (PDL)
Independence Blue Cross reissued MA11.071b on 04/01/2026 to reaffirm its coverage position on selective photothermolysis using pulsed-dye lasers (PDL). The policy clarifies that PDL treatment for psoriasis, molluscum contagiosum, basal cell carcinoma, cutaneous lupus erythematosus, and cutaneous sarcoidosis remains experimental/investigational and non-covered. The policy also updated criteria for rosacea treatment to align with current clinical standards and added specific ICD-10 diagnosis codes for non-covered indications.
Independence Blue Cross · Effective Apr 1, 2026Medium impact
11.08.04i, Selective Photothermolysis Using Pulsed-Dye Lasers (PDL)
Independence Blue Cross reissued Policy 11.08.04i on 04/01/2026 reaffirming its continuing position on PDL treatment coverage. The policy clarifies medically necessary indications (port wine stains, hemangiomas, hypertrophic/keloidal scars, pyogenic granulomas, viral warts, and rosacea), designates specific conditions as experimental/investigational (psoriasis, molluscum contagiosum, basal cell carcinoma, cutaneous lupus), and updates rosacea treatment criteria to require 6-month failed medical management before PDL coverage. Billing teams must verify patient diagnoses against the expanded ICD-10 code list and confirm medical necessity documentation for rosacea cases.
Aetna · Identified Aug 19, 2026Medium impact
YAG Laser in Ophthalmology and Other Selected Indications (CPB 0354, reviewed 2026-05-21)
Aetna considers Nd:YAG laser capsulotomy medically necessary after cataract extraction in members with visually significant clouding of the posterior capsule, and considers Nd:YAG laser peripheral iridotomy medically necessary for acute primary angle closure, primary angle-closure glaucoma, plateau iris syndrome, aqueous misdirection, and before intraocular lens insertion into the anterior chamber to avoid post-operative iris bombe or pupil block. Capsulotomy performed within 6 months of cataract surgery is subject to medical necessity review, and it is considered experimental, investigational, or unproven if none of the stated criteria is met. Nd:YAG laser vitreolysis for vitreous floaters, posterior hyaloidotomy for pre-macular hemorrhage, goniopuncture for failed trabeculectomy, and peripheral iridotomy to prevent pigment dispersion glaucoma are considered experimental, investigational, or unproven, as are many non-ophthalmological uses such as basal cell carcinoma, benign prostatic hyperplasia, onychomycosis and snoring.
Aetna · Identified Aug 13, 2026Medium impact
Etanercept (CPB 0315, reviewed 2026-07-08)
Aetna's Clinical Policy Bulletin 0315 considers etanercept (Enbrel) medically necessary for rheumatoid arthritis, articular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis, reactive arthritis, hidradenitis suppurativa, graft versus host disease, Behcet's disease and immune checkpoint inhibitor-related toxicity when the listed criteria are met. Initial criteria differ by indication and include prior treatment with other drugs for several of them, and continuation of therapy requires a positive clinical response. Aetna considers all other indications experimental, investigational, or unproven, including concomitant use with another biologic or targeted synthetic drug for the same indication.

Watch L40.8

Get one email when a payer policy names L40.8, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

MA11.071b, Selective Photothermolysis Using Pulsed-Dye Lasers (PDL)

11.08.04i, Selective Photothermolysis Using Pulsed-Dye Lasers (PDL)

YAG Laser in Ophthalmology and Other Selected Indications (CPB 0354, reviewed 2026-05-21)

Etanercept (CPB 0315, reviewed 2026-07-08)

What insurance policy changes affect code L40.8?

Which payers have updated policy for code L40.8?

How do I get notified when code L40.8 policy changes?

Why do payers change policies for code L40.8?